[(6-氧代-7,8,9,10-四氢-6H-苯并[c]苯并吡喃-3-基)氧基]乙酸 | 325737-63-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: [(6-氧代-7,8,9,10-四氢-6H-苯并[c]苯并吡喃-3-基)氧基]乙酸
• 中文别名: [(6-氧代-7,8,9,10-四氢-6H-苯并[C]苯并吡喃-3-基)氧基]乙酸
• 英文名称: 2-[(7,8,9,10-tetrahydro-6-oxo-6H-dibenzo[b,d]pyran-3-yl)oxy]acetic acid
• 英文别名: 2-(7,8,9,10-tetrahydro-6-oxo-6H-benzo[c]chromen-3-yloxy)acetic acid；[(6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy]acetic acid；2-[(6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl)oxy]acetic acid
• CAS: 325737-63-1
• 化学式: C₁₅H₁₄O₅
• mdl: MFCD01547660
• 分子量: 274.273
• InChiKey: VSLUULHUGBODEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  [(6-氧代-7,8,9,10-四氢-6H-苯并[c]苯并吡喃-3-基)氧基]乙酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 6.5h， 生成 3-(2-morpholino-2-oxoethoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one
  参考文献：
  名称：

  新型尿石素酰胺作为抗阿尔茨海默病的多靶点药物的设计、合成和生物学评价

  摘要：

  设计合成了一系列尿石素酰胺（即URO-4 - URO-10和THU-4 - THU-10）衍生物，并通过光谱技术和元素分析对其化学结构进行了确认。评估了标题化合物和合成中间体（THU-1 - THU-10和URO-1 - URO-10）抑制乙酰胆碱酯酶 (AChE)、丁酰胆碱酯酶 (BuChE) 和单胺氧化酶 B (MAO-B) 的潜力。化合物THU-4和THU-8分别是胆碱酯酶和 MAO-B 的最有效抑制剂。对接研究还用于评估最活跃的化合物与 AChE、BuChE 和 MAO-B 的结合模式。此外，在β淀粉样蛋白抑制和抗氧化分析系统中，这些化合物的中度至强活性也显示出来。结果指出，尿石素支架可用于药物设计研究，以开发作用于各种级联的多靶标配体，这些级联在阿尔茨海默病的病理生理学中很重要。

  DOI：

  10.1002/ardp.202000467
• 作为产物：
  描述：

  尿石素B 在 sodium hydroxide 、 potassium carbonate 作用下， 以 异丙醇 、 丙酮 为溶剂， 反应 4.0h， 生成 [(6-氧代-7,8,9,10-四氢-6H-苯并[c]苯并吡喃-3-基)氧基]乙酸
  参考文献：
  名称：

  摘要：

  Peptide-chemistry methods (symmetric anhydrides and activated esters) and the Mannich reaction were used to prepare various conjugates of amino acids with 7,8,9, 10-tetrahydrobenzo[c]chromen-6-one in which the amino acids are bound to the coumarin by the C- or N-terminus.

  DOI：

  10.1023/a:1022151407961

文献信息

• Modified Coumarins. 35. Synthesis of Coumarins Containing a Lupinine Moiety
  作者：Yu. A. Nikitina、A. I. Galaev、Ya. L. Garazd、M. M. Garazd、V. G. Kartsev

  DOI：10.1007/s10600-016-1545-3

  日期：2016.1

  New coumarin derivatives containing a lupinine moiety were prepared via amidation of coumarinyloxyacetic, coumarinylacetic, and coumarinylpropionic acids by lupinamine.

  通过羽扇豆胺对香豆素氧乙酸、香豆素乙酸和香豆素丙酸的酰胺化作用，制备出了含有羽扇豆碱分子的新型香豆素衍生物。
• Modified coumarins. 22. Synthesis of N-coumarinyloxyacetyl derivatives of cytisine
  作者：I. P. Dubovik、M. M. Garazd、V. I. Vinogradova、V. P. Khilya

  DOI：10.1007/s10600-006-0061-2

  日期：2006.3

  N-Acetyl derivatives of cytisine modified by coumarins were synthesized.

  合成了由香豆素修饰的N-乙酰胞嘧啶衍生物。
• [EN] DNA-ENCODED CHEMICAL LIBRARIES<br/>[FR] BIBLIOTHÈQUES DE PRODUITS CHIMIQUES CODÉS PAR ADN
  申请人：PHILOCHEM AG

  公开号：WO2009077173A2

  公开（公告）日：2009-06-25

  A method of preparing a DNA-encoded chemical library comprising members which comprise a chemical moiety, a linking moiety and a DNA moiety, comprising for each member the steps of: (I) coupling a initial building block to a initial coding single strand oligomer via a linking moiety to form a initial conjugate, the initial coding single strand oligomer comprising a first primer region, an initial coding region and a first annealing region; (II) optionally coupling a middle building block and middle coding single strand oligomer to said initial conjugate to form a middle conjugate, the coupling take place in either order, wherein: (a) the middle building block is coupled to the residue of the initial building block; and (b) the middle coding single strand oligomer comprises a middle coding region and second annealing region, and is coupled by: (i) annealing a complementary single strand oligomer which comprises a chemical modifier, a complementary first annealing region, a complementary middle coding region and a complementary second annealing region by interaction between the first annealing region and the complementary first annealing region; (ii) treating the conjugate formed with a DNA polymerase to elongate the initial coding single strand oligomer to be complementary to the complementary middle coding region and the complementary second annealing region; (iii) removing the complementary single strand oligomer by denaturing the DNA and capturing the complementary single strand oligomer via the chemical modifier; (III) coupling a final building block and final coding single strand oligomer to the initial or middle conjugate as appropriate to form a final conjugate, the coupling take place in either order, wherein: (a) the final building block is coupled to the residue of the initial building block, or may be additionally or alternatively be coupled to the residue of the middle building block (if present); and (b) the final coding single strand oligomer comprises a final coding region and a second primer region, and is coupled by: (i) annealing a complementary single strand oligomer which comprises a complementary first or second annealing region as appropriate, a complementary final coding region and a complementary second primer region, by interaction between the first or second annealing region and the complementary first or second annealing region, as appropriate; (ii) treating the conjugate formed with a DNA polymerase to elongate the initial coding single strand oligomer to be complementary to the complementary final coding region and the complementary second primer region, and to elongate the complementary coding strand to be complementary to the initial coding single strand oligomer.
• ——
  作者：M. M. Garazd、Ya. L. Garazd、S. V. Shilin、V. P. Khilya

  DOI：10.1023/a:1022151407961

  日期：——

  Peptide-chemistry methods (symmetric anhydrides and activated esters) and the Mannich reaction were used to prepare various conjugates of amino acids with 7,8,9, 10-tetrahydrobenzo[c]chromen-6-one in which the amino acids are bound to the coumarin by the C- or N-terminus.
• Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease
  作者：Karar T. Shukur、Tugba Ercetin、Chiara Luise、Wolfgang Sippl、Okan Sirkecioglu、Mert Ulgen、Goknil P. Coskun、Mine Yarim、Mustafa Gazi、Hayrettin O. Gulcan

  DOI：10.1002/ardp.202000467

  日期：2021.5

  URO‐4–URO‐10 and THU‐4–THU‐10) derivatives was designed and synthesized, and their chemical structures were confirmed with spectroscopic techniques and elemental analysis. The title compounds and synthesis intermediates (THU‐1–THU‐10 and URO‐1–URO‐10) were evaluated for their potential to inhibit acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase B (MAO‐B). Compounds THU‐4

  设计合成了一系列尿石素酰胺（即URO-4 - URO-10和THU-4 - THU-10）衍生物，并通过光谱技术和元素分析对其化学结构进行了确认。评估了标题化合物和合成中间体（THU-1 - THU-10和URO-1 - URO-10）抑制乙酰胆碱酯酶 (AChE)、丁酰胆碱酯酶 (BuChE) 和单胺氧化酶 B (MAO-B) 的潜力。化合物THU-4和THU-8分别是胆碱酯酶和 MAO-B 的最有效抑制剂。对接研究还用于评估最活跃的化合物与 AChE、BuChE 和 MAO-B 的结合模式。此外，在β淀粉样蛋白抑制和抗氧化分析系统中，这些化合物的中度至强活性也显示出来。结果指出，尿石素支架可用于药物设计研究，以开发作用于各种级联的多靶标配体，这些级联在阿尔茨海默病的病理生理学中很重要。